Overview
Fengying Wu practices in Shanghai, China. Wu is rated as an Advanced expert by MediFind in the treatment of EGFR Positive Lung Cancer. Their top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.
Their clinical research consists of co-authoring 87 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 7 articles in the study of EGFR Positive Lung Cancer.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- EGFR Positive Lung Cancer
- Lung Adenocarcinoma
- Lung CancerWu isAdvanced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Experienced
- Acute Interstitial Pneumonia
- Interstitial Lung Disease
- Lung MetastasesWu isExperienced. Learn about Lung Metastases.
- Metastatic Pleural Tumor
- Osteolysis Syndrome Recessive
- Papillary Thyroid Cancer